Methods For Treating Diabetes With Alternating Electric Fields
Disclosed are methods of treating that can be performed using alternating electric fields applied in a single direction or multiple directions. Disclosed are method of treating a subject having diabetes comprising applying alternating electric fields to a target site of the subject for a period of time, the alternating electric fields having a frequency and field strength, wherein FGF21 is increased in the subject.
1 . A method of treating a subject having diabetes comprising applying an alternating electric field to a target site of the subject for a period of time, the alternating electric field having a frequency and field strength,
wherein FGF21 is increased in the subject.
2 . A method of treating a subject comprising: identifying a subject with diabetes, applying an alternating electric field to a target site of the subject for a period of time, the alternating electric field having a frequency and field strength,
wherein FGF21 is increased in the subject.
3 . A method of treating a subject comprising: identifying a subject with diabetes, wherein the subject has a target site that is identified as being tumor-free, applying an alternating electric field to the target site of the subject for a period of time, the alternating electric field having a frequency and field strength,
wherein FGF21 is increased in the subject.
4 . A method of treating a subject comprising: identifying a subject with diabetes, wherein the subject is also identified as being tumor-free, applying an alternating electric field to a target site of the subject for a period of time, the alternating electric field having a frequency and field strength,
wherein FGF21 is increased in the subject.
5 . The method of any one of claims 1 - 4 , wherein the target site comprises hepatocytes.
6 . The method of any one of claims 1 - 4 , wherein the target site is the subject's liver.
7 . The method of any one of claims 1 - 4 , wherein the target site is the subject's torso.
8 . The method of any one of claims 1 - 7 , further comprising administering a diabetes therapeutic to the subject.
9 . The method of any one of claims 1 - 8 , wherein the subject is not diagnosed with liver cancer.
10 . The method of any one of claims 1 - 8 , wherein the subject is not diagnosed with a tumor.
11 . The method of any one of claims 8 - 10 , wherein the diabetes therapeutic is administered prior to applying the alternating electric fields.
12 . The method of any one of claims 8 - 10 , wherein the diabetes therapeutic is administered after applying the alternating electric fields.
13 . The method of any one of claims 8 - 10 , wherein the diabetes therapeutic is administered simultaneously with applying the alternating electric fields.
14 . The method of any one of claims 1 - 13 , wherein the frequency of the alternating electric fields is between 50 kHz and 10 MHz.
15 . The method of claim 14 , wherein the frequency of the alternating electric fields is about 200 kHz.
16 . The method of any one of claims 1 - 15 , wherein the field strength is between 0.5 V/cm and 10 V/cm.
17 . The method of claim 16 , wherein the field strength is 1 V/cm.
18 . The method of any one of claims 8 - 17 , wherein the diabetes therapeutic is metformin, a sulfonylurea, a glinide, a thiazolidinedione, a GLP-1 receptor agonist, or an SGLT2 inhibitor.
19 . The method of any one of claims 1 - 18 , wherein the subject having diabetes has type 2 diabetes.
20 . The methods of any of claims 1 - 19 , wherein a magnetic field is not applied to the subject.
21 . A method of increasing FGF21 in a subject having diabetes comprising: applying an alternating electric field to a target site of the subject for a period of time, the alternating electric field having a frequency and field strength,
wherein FGF21 is increased in the subject.
22 . A method of increasing blood glucose uptake in a subject having diabetes comprising: applying an alternating electric field to a target site of the subject for a period of time, the alternating electric field having a frequency and field strength,
wherein FGF21 is increased in the subject.
23 . A method of increasing brain-derived neurotrophic factor (BDNF) in a subject having diabetes comprising: applying an alternating electric field to a target site of the subject for a period of time, the alternating electric field having a frequency and field strength,
wherein FGF21 and BDNF are increased in the subject.
24 . A method of treating a subject having diabetes comprising applying an alternating electric field to a target site of the subject for a period of time, the alternating electric field having a frequency and field strength,
wherein FGF21 is increased in the subject.
25 . A method of treating a subject comprising: identifying a subject with diabetes, applying an alternating electric field to a target site of the subject for a period of time, the alternating electric field having a frequency and field strength,
wherein FGF21 is increased in the subject.
26 . A method of treating a subject comprising: identifying a subject with diabetes, wherein the subject is also identified as being tumor-free, applying an alternating electric field to a target site of the subject for a period of time, the alternating electric field having a frequency and field strength,
wherein FGF21 is increased in the subject.
27 . The methods of any of claims 24 - 26 , wherein a magnetic field is not applied to the subject.
28 . The method of any of claims 21 - 27 , wherein the target site comprises hepatocytes.
29 . The method of any one of claims 21 - 28 , wherein the target site is the subject's liver.
30 . The method of any one of claims 21 - 29 , wherein the target site is the subject's torso.
31 . The method of any one of claims 21 - 30 , further comprising administering a diabetes therapeutic to the subject.
32 . The method of any one of claims 21 - 31 , wherein the subject is not diagnosed with a tumor of the liver.
33 . The method of any one of claims 21 - 31 , wherein the subject is not diagnosed with a tumor.
34 . The method of any one of claims 31 - 33 , wherein the diabetes therapeutic is administered prior to applying the alternating electric fields.
35 . The method of any one of claims 31 - 33 , wherein the diabetes therapeutic is administered after applying the alternating electric fields.
36 . The method of any one of claims 21 - 33 , wherein the diabetes therapeutic is administered simultaneously with applying the alternating electric fields.
37 . The method of any one of claims 21 - 36 , wherein the frequency of the alternating electric fields is between 50 kHz and 10 MHz.
38 . The method of claim 37 , wherein the frequency of the alternating electric fields is about 200 kHz.
39 . The method of any one of claims 21 - 38 , wherein the field strength is between 0.5 V/cm and 10 V/cm.
40 . The method of claim 39 , wherein the field strength is 1 V/cm.
41 . The method of any one of claims 31 - 40 , wherein the diabetes therapeutic is metformin, a sulfonylurea, a glinide, a thiazolidinedione, a GLP-1 receptor agonist, or an SGLT2 inhibitor.
42 . The method of any one of claims 21 - 41 , wherein the subject having diabetes has type 2 diabetes.
43 . The methods of any of claims 21 - 42 , wherein a magnetic field is not applied to the subject.